Deramiocel Shows Long-Term Efficacy in Duchenne Muscular Dystrophy Treatment
Capricor Therapeutics announced positive three-year data from its open-label extension of the HOPE-2 clinical trial for deramiocel, a cell-based...
Cellphire Therapeutics gets FDA Fast Track for CLPH-511
Cellphire Therapeutics has received FDA Fast Track Designation for CLPH-511, a frozen activated platelet injectable suspension designed to treat...
PEP-010 Awarded FDA Orphan Drug Status for Pancreatic Cancer
PEP-Therapy’s lead product, PEP-010, a first-in-class bifunctional therapeutic peptide, received Orphan Drug Designation from the FDA for the treatment...
Radiopharm Theranostics: Rad202 Shows Positive Tumor Uptake & Biodistribution
Radiopharm Theranostics presented data at EMIM 2025 demonstrating the effectiveness of RAD202, a HER2-targeting single domain antibody, for both...
Bitterroot Bio Presents Phase 1 BRB-002 Results at ACC.25
Bitterroot Bio will present Phase 1 study results for BRB-002, a novel anti-CD47 therapy for atherosclerotic cardiovascular disease (ASCVD),...
Curevo Raises $110M for Shingles Vaccine
Curevo Vaccine secured $110 million in Series B funding to advance the development of its shingles vaccine, amezosvatein. The...
Exopten Shows Promise in Spinal Cord Injury Recovery
NurExone Biologic Inc. has successfully completed a preclinical study of its ExoPTEN treatment for spinal cord injuries, demonstrating significant...
Gradalis Unveils Clonal Tumor Mutation Burden Pipeline
Gradalis, a clinical-stage biotech company, published a peer-reviewed article in Scientific Reports detailing their novel exome sequencing procedure and...
KRRO-110 FDA Orphan Drug Designation for A1AD Deficiency
Korro Bio announced that its investigational medicine, KRRO-110, received orphan drug designation from the FDA for treating Alpha-1 Antitrypsin...
Gain Therapeutics Doses First Patient in Phase 1b Parkinson’s Trial
Gain Therapeutics has dosed the first Parkinson’s disease patient in a Phase 1b clinical trial of its lead candidate,...